Influence of guanidine on proteinase K resistance in vitro and infectivity of scrapie prion protein PRPSc

Acta Virologica

Volumn 50, Issue 1, 2006, Pages 25-32

  Gao, J M ^a   Zhou, X B ^a,b   Xiao, X L ^a,b   Zhang, J ^a,b   Chen, L ^a,c   Gao, C ^a   Zhang, B Y ^a   Dong, X P ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Guanidine; Infectivity; Prions; Proteinase K; PrPsc; Scrapie

Indexed keywords

GUANIDINE; PRION PROTEIN; PROTEINASE K;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN TISSUE; CONTROLLED STUDY; DENATURATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HAMSTER; IN VITRO STUDY; INFECTION; NONHUMAN; SCRAPIE; ANIMAL; CHEMISTRY; PROTEIN DENATURATION; SOLUBILITY; SYRIAN HAMSTER;

CRICETINAE; SCRAPIE PRION;

ANIMALS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASE K; FEMALE; GUANIDINE; MESOCRICETUS; PROTEIN DENATURATION; PRPSC PROTEINS; SOLUBILITY;

EID: 33646440631     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Bolton DC, Bendheim PE, Marmorstein AD, Potempska A (1987): Isolation and structural studies of the intact scrapie agent protein. Arch. Biochem. Biophys. 258, 579-590.
2. Brown DR, Hafiz F, Glasssmith LL, Wong BS, Jones IM, Clive C, Haswell SJ (2000): Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J. 19, 1180-1186.
3. Callahan MA, Xiong L, Caughey B (2001): Reversibility of scrapie-associated prion protein aggregation. J. Biol. Chem. 276, 28022-28028.
4. Caughey B, Kocisko DA, Raymond GJ, Lansbury PT Jr (1995): Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem. Biol. 2, 807-817.
5. Caughey B, Raymond GJ, Kocisko DA, Lansbury PT Jr (1997): Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J. Virol. 71, 4107-4110.
6. Caughey B, Raymond GJ, Priola SA, Kocisko DA, Race RE, Bessen RA, Lansbury PT Jr, Chesebro B (1999): Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. Mol. Biotechnol. 13, 45-55.
7. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey WS (1991): Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 30, 7672-7680.
8. Chen SG, Parchi P, Brown P, Capellari S, Zou W, Cochran EJ, Vnencak-Jones CL, Julien J, Vital C, Mikol J, Lugaresi E, Autilio-Gambetti L, Gambetti P (1997): Allelic origin of the abnormal prion protein isoform in familial prion diseases. Nat. Med. 3, 1009-1015.
9. Collinge J, Beck J, Campbell T, Estibeiro K, Will RG (1996): Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease. Lancet 348, 56.
10. Diringer H, Gelderblom H, Hilmert H, Ozel M, Edelbluth C, Kimberlin RH (1983): Scrapie infectivity, fibrils and low molecular weight protein. Nature 306, 476-478.
11. Sc in brain tissues of golden hamsters infected with scrapie strain 263K revealed various PrP forms. Biomed. Environ. Sci. 17, 8-20.
12. Gasset M, Baldwin MA, Fletterick RJ, Prusiner SB (1993): Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity. Proc. Natl. Acad. Sci. USA 90, 1-5.
13. Hill AF, Antoniou M, Collinge J (1999): Protease-resistant prion protein produced in vitro lacks detectable infectivity. J. Gen. Virol. 80, 11-14.
14. Hsiao KK, Groth D, Scott M, Yang SL, Serban H, Rapp D, Foster D, Torchia M, Dearmond SJ, Prusiner SB (1994): Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proc. Natl. Acad. Sci. USA 91, 9126-9130.
15. Jackson GS, Hosszu LL, Power A, Hill AF, Kenney J, Saibil H, Craven CJ, Waltho JP, Clarke AR, Collinge J (1999): Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 283, 1935-1937.
16. James TL, Liu H, Ulyanov NB, Farr-Jones S, Zhang H, Donne DG, Kaneko K, Groth D, Mehlhorn I, Prusiner SB, Cohen FE (1997): Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proc. Natl. Acad. Sci. USA 94, 10086-10091.
17. Kaneko K, Peretz D, Pan KM, Blochberger TC, Wille H, Gabizon R, Griffith OH, Cohen FE, Baldwin MA, Prusiner SB (1995): Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Proc. Natl. Acad. Sci. USA 92, 11160-11164.
18. KIimberlin RH, Walker CA (1978): Evidence that the transmission of one source of scrapie agent hamsters involves separation of agent strains from a mixture. J. Gen. Virol. 39, 487-496.
19. KIimberlin RH, Walker CA (1977): Characteristics of a short incubation model of scrapie in the golden hamster. J. Gen. Virol. 34, 295-304.
20. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B (1994): Cell-free formation of protease-resistant prion protein. Nature 370, 471-474.
21. Kocisko DA, Lansbury PT Jr, Caughey B (1996): Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. Biochemistry 35, 13434-13442.
22. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, Fournier JG, Hauw JJ, Rossier J, Dormont D (1997): Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275, 402-405.
23. McKenzie D, Bartz J, Mirwald J, Olander D, Marsh R, Aiken J (1998): Reversibility of scrapie inactivation is enhanced by copper. J. Biol. Chem. 273, 25545-25547.
24. McKinley MP, Bolton DC, Prusiner SB (1983): A protease-resistant protein is a structural component of the scrapie prion. Cell 35, 57-62.
25. Meyer RK, McKinley MP, Bowman KA, Braunfeld MB, Barry RA, Prusiner SB (1986): Separation and properties of cellular and scrapie prion proteins. Proc. Natl. Acad. Sci USA 83, 2310-2314.
26. Morillas M, Vanik DL, Surewicz WK (2001): On the mechanism of alpha-helix to beta-sheet transition in the recombinant prion protein. Biochemistry 40, 6982-6987.
27. Nandi PK, Leclerc E (1999): Polymerization of murine recombinant prion protein in nucleic acid solution. Arch. Virol. 144, 1751-1763.
28. Prusiner SB (1998): Prions. Proc. Natl. Acad. Sci. USA 95, 13363-13383.
29. Quaglio E, Chiesa R, Harris DA (2001): Copper converts the cellular prion protein into a protease resistant species that is distinct from the scrapie isoform. J. Biol. Chem. 276, 11432-11438.
30. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K (1996): NMR structure of the mouse prion protein domain PrP (121-321). Nature 382, 180-182.
31. Roher AE, Palmer KC, Chau V, Ball MJ (1988): Isolation and chemical characterization of Alzheimer's disease paired helical filament cytoskeletons: differentiation from amyloid plaque core protein. J. Cell Biol. 107, 2703-2716.
32. Safar J, Roller PP, Gajdusek DC, Gibbs CJ Jr (1993): Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. J. Biol. Chem. 268, 20276-20284.
33. Safar J, Roller PP, Gajdusek DC, Gibbs CJ Jr (1993): Thermal stability and conformational transitions of scrapie amyloid (prion) protein correlate with infectivity. Protein Sci. 2, 2206-2216.
34. Shaked GM, Meiner Z, Avraham I, Taraboulos A, Gabizon R (2001): Reconstitution of prion infectivity from solubilized protease-resistant PrP and nonprotein components of prion rods. J. Biol. Chem. 276, 14324-14328.
35. Stockel J, Hartl FU (2001): Chaperonin-mediated de novo generation of prion protein aggregates. J. Mol. Biol. 313, 861-872.
36. Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, Mastrianni J, Lugaresi E, Gambetti P, Prusiner SB (1996): Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274, 2079-2082.
37. Weber DJ, Rutala WA (2002): Managing the risk of nosocomial transmission of prion diseases. Curr. Opin. Infect. Dis. 15, 421-425.
38. Weissmann C (1999): Molecular genetics of transmissible spongiform encephalopathies. J. Biol. Chem. 274, 3-6.
39. Xiong LW, Raymond LD, Hayes SF, Raymond GJ, Caughey B (2001): Conformational change, aggregation and fibril formation induced by detergent treatments of cellular prion protein. J. Neurochem. 79, 669-678.
40. Yao HL, Han J, Zhang BY, Gao JM, Guo YJ, Zhang J, Xiao XL, Nie K, Cai CX, Dong XP (2004): Effects of several chemical and physical treatments on the protease resistance of scrapie strain 263K. Chin. J. Virol. 20, 40-45.
41. C as HIS-fusion form in a baculovirus system and conversion of expressed PrP-sen to PrP-res in a cell-free system. Virus Res. 87, 145-153.
42. Zhang J, Chen L, Zhang BY, Han J, Xiao XL, Tian HY, LI BL, Gao C, Gao JM, Zhou XB, Ma GP, Liu Y, Xu CM, Dong XP (2004): Comparison study on clinical and neuropathological characteristics of hamsters inoculated with scrapie strain 263K in different challenging pathways. Biomed. Environ. Sci. 17, 65-78.
43. Sc-like form. J. Biol. Chem. 277, 43942-43947.